CN108276415B - A kind of alkoxide triazol tetrazine kind compound and its preparation method and application - Google Patents
A kind of alkoxide triazol tetrazine kind compound and its preparation method and application Download PDFInfo
- Publication number
- CN108276415B CN108276415B CN201810128673.3A CN201810128673A CN108276415B CN 108276415 B CN108276415 B CN 108276415B CN 201810128673 A CN201810128673 A CN 201810128673A CN 108276415 B CN108276415 B CN 108276415B
- Authority
- CN
- China
- Prior art keywords
- compound
- triazol
- alkoxide
- preparation
- tetrazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention relates to a kind of alkoxide triazol tetrazine kind compounds and its preparation method and application, belong to technical field of medicine synthesis.In order to solve the problems, such as it is existing such compound activity do not study, a kind of alkoxide triazol tetrazine kind compound and its preparation method and application is provided, the preparation method of the compound includes by 6- (3,5- dimethyl pyrazole -1- base)-[1,2,4] triazole [4,3-b] heating balanced class compound and alkylol R1OH is reacted, and product type I compound alkoxide triazol tetrazine kind compound is obtained, and can be used in drug or functional food that preparation prevents and treats anti-tumor activity.The compound of the present invention structure novel and have preferable bioactivity, especially to tumour cell have preferable resistancing action.Method has reaction route short, and cost of material is low, easily operated, and the yield and purification effect of reaction.
Description
Technical field
The present invention relates to a kind of alkoxide triazol tetrazine kind compounds and its preparation method and application, belong to pharmaceutical synthesis
Technical field.
Background technique
Heating balanced derivative compound is a kind of with active compound is managed compared with Johnson & Johnson, is had by many document reports
Preferable antibacterial, anti-tumor activity, cause the extensive concern of many scholars and researcher.As Rao, G.W. et al. exist
Bioorganic&Medicinal Chemi stryLetters, the 1- acyl group-3,6- reported in 2005,15,3174-3176.
Disubstituted benzenes -1,2- dihydro-heating balanced class compound also has preferable inhibition antitumaous effect, wherein 1- monoxone acyl group -3,
6- phenyl -1,2- dihydro heating balanced has stronger anti-tumor capacity to its mouse leukemia cell P-388 and adenocarcinoma of lung A-549
(its inhibiting rate under the concentration of 10-5mol/L is 100% and 95.8% respectively).For another example Xu, F. et al. once reported [1,2,
4] triazole [4,3-b] heating balanced derivative compound has stronger anti-tumor activity, has stronger inhibition to c-Met receptor
Activity.Bekker et al. once reported that triazol tetrazine kind compound had good inhibiting effect to tubercle bacillus.And it is existing
[1,2,4] triazole [4,3-b] heating balanced derivative compound is often to bicyclic 3 or 6 progress structural modifications, especially pair
More in 6 modifications, synthetic method is general are as follows: contains easy leaving group (such as 3,5- dimethyl pyrazole -1- base, miaow for 6
Azoles -1- base etc.) [1,2,4] triazole [4,3-b] heating balanced derivative compound react to obtain 6 with alkylamino or nitrogen-containing heterocycle
[1,2,4] triazole [4,3-b] heating balanced derivative compound that alkanamine or arylamine replace.
Chinese patent (Authorization Notice No.: CN103012410B) as the present inventor applies discloses one kind with antitumor
Active [1,2,4] triazole [4,3-b] heating balanced derivative compound and preparation method thereof, by contain leaving group on 6-
[1,2,4] triazole [4,3-b] heating balanced derivative compound of 3,5- dimethyl pyrazole -1- base and alkylamino or fragrant amino etc. carry out
Reaction obtains.Although preferable active by thering is alkylamino or fragrant amino group to have in 6- substitutions, in existing report
It is by introducing the unit structures such as alkane ammonia, but so far for extremely, there are no the heating balanceds of 6- alkoxies of document report substitution to spread out
The bioactivity of biology, and also without reporting the similar synthetic method by introducing alkoxy at 6-.
Summary of the invention
The present invention is directed to the above defect existing in the prior art, propose a kind of alkoxide triazol tetrazine kind compound and
Preparation method and application are solving the problems, such as first is that how to improve a kind of new compound with anti-tumor activity；It solves
The problem of second is that synthetic method how to be made to have reaction route short and by-product is few.
An object of the present invention technical scheme is that, a kind of alkoxide triazol tetrazine class
Close object, which is characterized in that the structural formula of the compound is as shown in following formula I:
In above-mentioned formula I, R1Selected from C1~C5Alkyl；R2Selected from phenyl, substituted-phenyl or substituted benzene alkyl.
Alkoxide triazol tetrazine kind compound of the present invention is that in patent document, (authorization is public in further research the present inventor
Announcement number: [1,2,4] triazole [4,3-b] the heating balanced derivative compounds with anti-tumor activity provided in CN103012410B)
The a new class of compound with triazole heating balanced structure parent nucleus class being had been surprisingly found that during object, due in the patent document
Compound synthesis process in the solvent that uses containing alcoholic solvent when, [1,2,4] triazole [4,3-b] heating balanced for will obtaining
The presence of a small amount of alkoxide triazol tetrazine compound was had found (at that time only during derivative compound progress structural analysis
Analyzed with impurity), and carry out anti-tumor activity analysis during, finding the presence of the impurity, there is no to active constituent
Generate excessive influence.Therefore, in order to study whether the alkoxide triazol tetrazine compound has bioactivity, the present inventor
Alkoxide triazol tetrazine kind compound of the invention is filtered out after largely studying, by drawing on the position the 6- of heating balanced
After entering alkoxy grp, it is found that it equally exists preferable bioactivity, and the alkoxide triazol tetrazine class that the present invention screens
Object is closed to tumour cell inhibiting effect with higher, compared with generally acknowledged cis-platinum, comparable inhibitory effect can be reached, even
It will be far better than the function and effect of cis-platinum to the inhibiting effect of some tumour cells.Such as alkoxide triazol tetrazine class of the invention
Compound will be much better than the effect of cis-platinum to the inhibiting effect of human breast carcinoma MCF-7.This is just current research anti-tumor activity
Drug provide higher medicament selection space, make that there are more selectivity, make to be conducive to study safer, more reliable
Anti-tumor drug guarantees the safety of medication.
In above-mentioned alkoxide triazol tetrazine kind compound, the substituted-phenyl can be halogenophenyl, as chlorine takes
It for phenyl, fluorine substituted-phenyl, and can be monosubstituted or polysubstituted on the phenyl ring of phenyl, be also possible to C1-C3Alkyl-substituted benzene
Base, such as o-, m- or p- aminomethyl phenyl or ethylphenyl equally can be monosubstituted or polysubstituted；Benzene alkyl can be benzene second
Base or benzyl etc..Preferably, the R1Selected from methyl, ethyl, isobutyl group or isopropyl；R2It is selected from phenyl, to methoxy
Base phenyl, phenethyl, 2,4 dichloro benzene base, rubigan or p-fluorophenyl.Not only there is preferable anti-tumor activity, and pass through
It is easier to introduce these alkoxy grps, makes to be more advantageous to synthesis.
The second object of the present invention is achieved by the following technical programs, a kind of alkoxide triazol tetrazine class
Close object preparation method, which is characterized in that this method include by II compound 6- of formula (3,5- dimethyl pyrazole -1- base)-[1,2,
4] triazole [4,3-b] heating balanced class compound and alkylol R1OH is reacted, and product type I compound is obtained；
R described above1Selected from C1~C5Alkyl；The R2Selected from phenyl, substituted-phenyl or substituted benzene alkyl.
By directlying adopt alkylol and 6- (3,5- dimethyl pyrazole -1- base)-[1,2,4] triazole [4,3-b] heating balanced
The reaction of class compound, can be very good to make the easy leaving group 3 on the wherein position 6-, 5- dimethyl pyrazole -1- base is taken by alkoxy
In generation, more importantly directlys adopt alkoxy and uses while can also making as reactant as solvent, anti-without in addition addition
Solvent is answered, the selectivity of reaction is substantially increased, avoids the generation of other by-products, can preferably improve the quality of product,
Certainly, be not limited in alkoxy here and additionally incorporate a small amount of solvent in solution system because this have no effect on reaction into
Row.
In the preparation method of above-mentioned alkoxide triazol tetrazine kind compound, preferably, the alkylol R1OH choosing
From methanol, ethyl alcohol, isopropanol or isopropanol.The alkoxide triazol tetrazine kind compound enabled to is with higher anti-swollen
Tumor activity, and these alkylols have steric hindrance small, are more advantageous to introducing, are conducive to the conversion ratio of raw material, improve product
Yield and purity Coriolis mass requirement；And also have the advantages that toxicity is low and at low cost.
In the preparation method of above-mentioned alkoxide triazol tetrazine kind compound, preferably, the temperature of the reaction is
40 DEG C~80 DEG C.Substantially make to be maintained at the recovered temperature of alkylol or less and carry out, has reaction condition mild, it is easily operated
Effect.As a further preference, temperature 50 C~reflux temperature of the reaction.
In the preparation method of above-mentioned alkoxide triazol tetrazine kind compound, preferably, the alkylol R1OH is same
Shi Zuowei reactant and solvent use, the alkylol R1OH is excessive.Dosage by the way that alkylol is added is excessive state, one
Reaction is participated in when aspect can guarantee it as reactant, can make (3,5- dimethyl pyrazole -1- base)-[1,2,4] raw material 6-
Triazole [4,3-b] heating balanced class compound can be more fully converted, and improve conversion ratio and product purity, and can also conduct
Solvent makes the progress for reacting milder make to be more advantageous to operation without additionally incorporating other class solvents.As further excellent
Choosing, II compound quality (g) of formula and alkylol R1The volume (mL) of OH is than being 1:20~30.Here alkylol can be with
It recycles and reuses.
In the preparation method of above-mentioned alkoxide triazol tetrazine kind compound, preferably, further including after reaction
Post-processing, the post-processing specifically:
Reaction solution after reaction is carried out alkylol is distilled off, adding ice ethyl alcohol makes that solid is precipitated, and is produced
Object type I compound.Product can be made preferably to be precipitated by the way that ice ethyl alcohol is added, improve the yield of product.
The specific reaction synthetic route of the preparation method of above-mentioned alkoxide triazol tetrazine kind compound of the invention can be with
It is indicated using following reaction equation:
The third object of the present invention technical scheme is that, a kind of alkoxide triazol tetrazine class
Close the application of object, which is characterized in that above-mentioned alkoxide triazol tetrazine kind compound, which is used to prepare, prevents and treats antitumor work
The drug or functional food of property.Due to outstanding representation of this alkoxide triazol tetrazine kind compound in terms of anti-tumor activity,
Here anti-tumor activity mainly for tumour include human lung cancer (A549), human placenia cancer cell line (Bewo) and human milk
Gland cancer (MCF-7), all has preferable inhibitory effect.As a further preference, the drug of the anti-tumor activity includes upper
State the active constituent and pharmaceutically acceptable auxiliary material of alkoxide triazol tetrazine kind compound.Here the dosage of active constituent can
To carry out selective adjustment according to actual drug effect dosage, there is no there is limitation to require.It can also be according to different drug agent
Type selects the dosage situation of active medicine, and pharmaceutical dosage form here can be tablet, liquid preparation or capsule and injection etc.
Deng dosage form.Certainly, pharmaceutically acceptable auxiliary material described above is also possible to according to different auxiliary of different dosage form selections
Expect ingredient and dosage situation.
In conclusion compared with prior art, the present invention having the advantage that
1. alkoxide triazol tetrazine kind compound of the invention is a kind of compound with novel structure, have compared with
Good bioactivity especially has preferable resistancing action to tumour cell.
2. being that raw material had not only been used as reactant to participate in reaction, but also can directly act on solvent use by using alkylol, have
Conducive to the generation for reducing by-product, the yield and purification effect of reaction is improved, and reaction route is short, only need single step reaction real
Existing, cost of material is low, easily operated, is conducive to industrialized production.
Specific embodiment
Below by specific embodiment, the technical solutions of the present invention will be further described, but the present invention is simultaneously
It is not limited to these embodiments.
Embodiment 1
The present embodiment is specially 3- p-fluorophenyl -6- isobutoxy-[1,2,4] triazole [4,3-b] heating balanced compound,
Structural formula is as shown in following formula I-a:
Above-mentioned Formulas I-a compound 3- p-fluorophenyl -6- isobutoxy-[1,2,4] triazole [4,3-b] heating balanced is specifically adopted
It obtains using the following method:
In the clean reaction flask of 100mL, addition raw material 3- p-fluorophenyl -6- (3,5- dimethyl pyrazole -1- base)-[1,
2,4] triazole [4,3-b] heating balanced 1g (3.4mmol) and isobutanol 30mL, then carries out heat temperature raising, and temperature is made to rise to 80 DEG C
Carry out reaction 5h；After reaction, it carries out removing extra solvent under reduced pressure, then obtained residue is added into residue
A small amount of ice ethyl alcohol, makes that a large amount of yellow solids are precipitated, and filters, drying, obtain target product 3- p-fluorophenyl -6- isobutoxy-[1,
2,4] triazole [4,3-b] heating balanced, yield 0.64g, yield 65.3%.
Obtained product is subjected to corresponding structural analysis, concrete analysis structure is as follows:
Wherein fusing point mp are as follows: 128~130 DEG C.
IRνmax(KBr)/cm-1: 3074.3,2973.5,1605.5,1546.8,1057.4,860.5.
1H-NMR(D6- DMSO, 400MHz) δ: 8.45 (t, 2H, J=8.8Hz), 7.52 (t, 2H, J=8.8Hz), 4.29
(d, 2H, J=6.3Hz), 2.23 (m, 1H), 1.06 (d, 2H, J=6.3Hz).
13C-NMR(D6- DMSO, 100MHz) δ: 165.2,159.4,152.1,144.3,130.1 (2C), 121.6,117.0
(2C),75.9,27.6,19.3(2C)。
MS (EI): m/z (%): 289.2 [(M+H)+,100]。
Anal.calcd for C13H13FN6O:C, 54.16；H,4.55；N,29.15；O,5.55；Found:C, 54.25；
H,4.54；N,29.12；O,5.57.
Embodiment 2
The present embodiment is specially 3- (2,4 dichloro benzene base) -6- ethyoxyl-[1,2,4] triazole [4,3-b] heating balanced chemical combination
Object, structural formula is as shown in following formula I-b:
The tool of above-mentioned Formulas I-b compound 3- (2,4 dichloro benzene base) -6- ethyoxyl-[1,2,4] triazole [4,3-b] heating balanced
Preparation is as follows:
In the reaction flask of 100mL cleaning, raw material 2,4- dichlorophenyl -6- (3,5- dimethyl pyrazole -1- base)-is added
[1,2,4] triazole [4,3-b] heating balanced 1g (2.8mmol) and dehydrated alcohol 30mL, carries out heat temperature raising for reaction solution, makes temperature
Reaction 8h is carried out under conditions of rising to 70 DEG C, after reaction, is evaporated under reduced pressure, and extra solvent is evaporated off, obtains residue,
A small amount of ice ethyl alcohol is added into residue again, makes that a large amount of yellow solid is precipitated, filters, obtains target product 3- (2,4- dichloros
Phenyl) -6- ethyoxyl-[1,2,4] triazole [4,3-b] heating balanced compound, yield 0.62g, yield 71.2%.
Obtained compound is subjected to relevant structural analysis, concrete analysis result is as follows:
Wherein fusing point mp are as follows: 146~148 DEG C；
IRνmax(KBr)/cm-1: 3098.3,2979.0,1595.8,1549.1,1051.5,826.0.
1H-NMR(D6- DMSO, 400MHz) δ: 7.97 (s, 1H), 7.80 (d, 1H, J=8.8Hz), 7.71 (d, 1H, J=
8.8Hz), 4.40 (q, 2H, J=7.0Hz), 1.06 (t, 3H, J=7.0Hz).
13C-NMR(D6- DMSO, 100MHz) δ: 159.5,151.5,143.7,137.6,134.8,134.1,130.7,
128.6,122.7,66.5,14.2。
MS (EI): m/z (%): 311.1 [(M+H)+,100],333.1[(M+Na)+,50]。
Anal.calcd for C11H8Cl2N6O:C, 42.46；H,2.59；N,27.01；O,5.14；Found:C, 42.57；
H,2.59；N,26.93；O,5.13.
Embodiment 3
The present embodiment is specially 3- (2,4- dichlorophenyl) -6- isopropoxy-[1,2,4] triazole [4,3-b] heating balanced,
Structural formula is as shown in following formula I-c:
The specific system of above-mentioned Formulas I-c compound 3- (2,4 dichloro benzene base) -6- isopropoxy-[1,2,4] triazole [4,3-b]
Preparation Method is as follows:
In the reaction flask of 100mL cleaning, raw material 2,4- dichlorophenyl -6- (3,5- dimethyl pyrazole -1- base)-is added
Then mixed reaction solution is carried out heating and risen by [1,2,4] triazole [4,3-b] heating balanced 1g (2.8mmol) and isopropanol 40mL
Temperature makes to carry out reaction 5h under conditions of being heated to 75 DEG C；After reaction, it then carries out that extra solvent is evaporated off, obtain
To residue, it is generally advisable to control temperature at 45 DEG C hereinafter, that a small amount of ice ethyl alcohol is added into residue is molten in vacuum distillation process
Agent makes that a large amount of yellow solid is precipitated, filter, drying, obtain target product 3- (2,4- dichlorophenyl) -6- isopropoxy-[1,
2,4] triazole [4,3-b], yield 0.68g, yield 74.7%.
Obtained product is subjected to corresponding structural analysis, concrete analysis structure is as follows:
Wherein fusing point mp are as follows: 128~130 DEG C.
IRνmax(KBr)/cm-1: 3094.1,2988.3,1546.8,1398.9,1053.1,824.2.
1H-NMR(D6- DMSO, 400MHz) δ: 7.98 (s, 1H), 7.79 (d, 1H, J=8.4Hz), 7.72 (d, 1H, J=
8.4Hz), 5.06 (sext, 1H, J=6.1Hz), 1.42 (d, 6H, J=4.1Hz).
13C-NMR(D6- DMSO, 100MHz) δ: 158.9,151.4,143.6,137.5,134.8,134.1,130.7,
128.5,122.7,74.8,21.5(2C)。
MS (EI): m/z (%): 325.1 [(M+H)+,100],347.1[(M+Na)+,23]。
Anal.calcd for C12H10Cl2N6O:C, 44.33；H,3.10；N,25.85；O, 4.92.Found:C,
44.43；H,3.11；N,25.92；O,4.91.
Embodiment 4
The present embodiment is specially 3- (4- fluorophenyl) -6- methoxyl group-[1,2,4] triazole [4,3-b] heating balanced, structural formula
As shown in following formula I-d:
The specific system of above-mentioned Formulas I-d compound 3- (4- fluorophenyl) -6- methoxyl group-[1,2,4] triazole [4,3-b] heating balanced
Preparation Method is as follows:
In the reaction flask of 100mL cleaning, addition raw material 4- fluorophenyl -6- (3,5- dimethyl pyrazole -1- base)-[1,2,
Mixed reaction solution is carried out heat temperature raising, makes to be warming up to 60 by 4] triazole [4,3-b] heating balanced 1g (3.2mmol) and methanol 30mL
DEG C reaction 6h is carried out, after reaction, carries out that solvent is evaporated off, then a small amount of ice ethyl alcohol is added into residue, make to analyse
A large amount of yellow solids out, filtering, drying, drying temperature are controlled at 40 DEG C -45 DEG C, obtain target product 3- (4- fluorophenyl) -6-
Methoxyl group-[1,2,4] triazole [4,3-b] heating balanced, yield 0.58g, yield 73.4%.
Obtained product is subjected to corresponding structural analysis, concrete analysis structure is as follows:
Wherein fusing point mp are as follows: 178~180 DEG C.
IR νmax(KBr)/cm-1: 3098.6,2976.7,1605.0,1559.2,1051.8,851.5.
1H-NMR(D6- DMSO, 400MHz) δ: 8.47-8.50 (m, 2H), 7.51 (dd, 2H, J1=10.0, J2=
8.0Hz),4.19(s,3H)。
13C-NMR(D6- DMSO, 100MHz) δ: 165.3,159.9,152.1,144.3,130.2 (2C), 121.5,117.0
(2C),57.2。
MS (EI): m/z (%): 247.2 [(M+H)+,100]。
Anal.calcd for C10H7FN6O:C, 48.78；H,2.87；N,34.13；O,6.50；Found:C, 48.69；
H,2.86；N,34.20；O,6.48.
Embodiment 5
The present embodiment is specially 3- (4- chlorphenyl) -6- methoxyl group-[1,2,4] triazole [4,3-b] heating balanced, structural formula
As shown in following formula I-e:
The preparation method of 3- (4- chlorphenyl) -6- methoxyl group-[1,2,4] triazole [4,3-b] heating balanced of the present embodiment is such as
Under:
In the reaction flask of 100mL cleaning, addition raw material 4- chlorphenyl -6- (3,5- dimethyl pyrazole -1- base)-[1,2,
4] triazole [4,3-b] heating balanced 1g (3.1mmol) and ethyl alcohol 30mL, heating, by the temperature of reaction solution be warming up to 65 DEG C -70 DEG C into
Row reaction 8h carries out that extra alcohol solvent is evaporated off, then dehydrated alcohol is added into residue after reaction
10mL, then slow cooling makes that a large amount of yellow solids are precipitated, filters, drying obtains to 0 DEG C of -5 DEG C of stirring and crystallizing under stirring
To target product 3- (4- chlorphenyl) -6- methoxyl group-[1,2,4] triazole [4,3-b] heating balanced, yield 0.52g, yield
68.4%.
Obtained product is subjected to corresponding structural analysis, concrete analysis structure is as follows:
Wherein fusing point mp are as follows: 220~222 DEG C.
IR νmax(KBr)/cm-1: 3089.9,2994.3,1538.6,1538.6,1053.9,851.3.
1H-NMR(D6- DMSO, 400MHz) δ: 8.41 (d, 2H, J=8.6Hz), 7.73 (d, 2H, J=8.6Hz), 4.56
(q, 2H, J=7.0Hz), 1.50 (t, 3H, J=7.0Hz).
13C-NMR(D6- DMSO, 100MHz) δ: 159.2,152.2,144.1,136.5,130.0 (2C), 129.3 (2C),
123.9,66.5,14.3。
MS (EI): m/z (%): 247.2 [(M+H)+,100]。
Anal.calcd for C11H9ClN6O:C, 47.75；H,3.28；N,30.37；O,5.78；Found:C, 47.90；
H,3.27；N,30.27；O,5.77.
Embodiment 6
The present embodiment is specially 3- (4- chlorphenyl) -6- methoxyl group-[1,2,4] triazole [4,3-b] heating balanced, structural formula
As shown in following formula I-f:
The specific system of 3- (2,4- dichlorophenyl) -6- isobutyl group-[1,2,4] triazole [4,3-b] heating balanced of the present embodiment
Preparation Method is as follows:
In the reaction flask of 100mL cleaning, raw material 2,4- dichlorophenyl -6- (3,5- dimethyl pyrazole -1- base)-is added
[1,2,4] triazole [4,3-b] heating balanced 1g (2.8mmol) and isobutanol 50mL, after mixing, reheating are to slowly warm up to 80
DEG C carry out reaction 5h, after reaction, be evaporated under reduced pressure, extra iso-butanol solvent is evaporated off, then, then into residue plus
Enter a small amount of ice ethyl alcohol, it is solid to make to be precipitated a large amount of yellow it is generally advisable to control in 5 DEG C or less progress crystallization processing for the temperature of ice ethyl alcohol
Body, filtering, drying, obtains target product 3- (2,4- dichlorophenyl) -6- isobutyl group-[1,2,4] triazole [4,3-b] heating balanced,
Yield is 0.70g, mass yield 73.7%.
Obtained product is subjected to corresponding structural analysis, concrete analysis structure is as follows:
Wherein fusing point mp are as follows: 168~170 DEG C.
IR νmax(KBr)/cm-1: 3058.3,2976.9,1582.6,1538.4,1038.4,821.4.
1H-NMR(D6- DMSO, 400MHz) δ: 7.97 (s, 1Hz), 7.80 (d, 1H, J=8.4Hz), 7.22 (d, 1H, J=
8.4Hz), 4.13 (d, 2H, J=6.4Hz), 2.14 (m, 1H), 1.00 (d, 6H, J=6.7Hz).
13C-NMR(D6- DMSO, 100MHz) δ: 159.7,151.5,143.6,137.6,134.8,134.0,130.7,
128.5,122.7,75.9,27.6,19.2(2C)。
MS (EI): m/z (%): 340.2 [(M+2)+,100],361.2[(M+Na)+,25]。
Anal.calcd for C13H12Cl2N6O:C, 46.03；H,3.57；N,24.78；O,4.72；Found:C,
46.12；H,3.57；N,24.70；O,4.70.
Embodiment 7
The present embodiment is specially 3- phenyl -6- ethyoxyl-[1,2,4] triazole [4,3-b] heating balanced, structural formula such as following formula
Shown in I-g:
3- phenyl -6- the ethyoxyl of the present embodiment-[1,2,4] triazole [4,3-b] heating balanced it is specific the preparation method is as follows:
In the reaction flask of 100mL cleaning, (3,5- dimethyl pyrazole -1- base)-[1,2,4] raw material 3- phenyl -6- is added
Triazole [4,3-b] heating balanced 1g (3.4mmol) and dehydrated alcohol 30mL, reaction mixture, which is carried out heating, makes temperature rise to 40
Reaction 10h is carried out in DEG C -45 DEG C, after reaction, is evaporated under reduced pressure, extra alcohol solvent is evaporated off, then into residue
A small amount of 5mL ice ethyl alcohol is added, and to be stirred crystallization complete, makes that a large amount of yellow solid is precipitated, filtering, drying obtain target product
3- phenyl -6- ethyoxyl-[1,2,4] triazole [4,3-b] heating balanced, yield 0.50g, mass yield 61.0%.
Obtained product is subjected to corresponding structural analysis, concrete analysis structure is as follows:
Wherein fusing point mp are as follows: 120~122 DEG C.
IRνmax(KBr)/cm-1: 3068.0,2986.4,1573.3,1540.8,1053.7,746.7,704.7.
1H-NMR(D6- DMSO, 400MHz) δ: 8.43-8.45 (m, 2H), 7.65~7.71 (m, 3H, ArH), 4.58 (q,
2H, J=7.0Hz), 1.53 (t, 3H, J=7.0Hz).
13C-NMR(D6- DMSO, 100MHz) δ: 159.2,154.3,152.2,151.5,144.9,144.1,131.8,
130.7,129.8,129.1,127.6,126.9,125.0,66.4,14.3.
MS (EI): m/z (%): 243.1 [(M+H)+,100]。
Anal.calcd for C11H10N6O:C, 54.54；H,4.16；N,34.69；O,6.60；Found:C, 54.61；H,
4.14；N,34.75；O,6.58.
Embodiment 8
The present embodiment is specially 3- phenethyl -6- ethyoxyl-[1,2,4] triazole [4,3-b] heating balanced, and structural formula is as follows
Shown in Formulas I-h:
The specific preparation method of the 3- phenethyl -6- ethyoxyl of the present embodiment-[1,2,4] triazole [4,3-b] heating balanced is such as
Under:
In the clean reaction flask of 100mL, addition raw material 3- phenethyl -6- (3,5- dimethyl pyrazole -1- base)-[1,2,
4] triazole [4,3-b] heating balanced 1g (3.1mmol) and dehydrated alcohol 40mL, heat temperature raising, rise to the temperature of reaction mixture
70 DEG C of heat preservations carry out reaction 7h, after reaction, are evaporated under reduced pressure, extra alcohol solvent is evaporated off, then add into residue
Enter a small amount of ice ethyl alcohol stirring and carry out crystallization, makes that a large amount of yellow solid is precipitated, filtering, drying obtain target product 3- phenethyl-
6- ethyoxyl-[1,2,4] triazole [4,3-b] heating balanced, yield 0.69g, mass yield 82.1%.
Obtained product is subjected to corresponding structural analysis, concrete analysis structure is as follows:
Wherein fusing point mp are as follows: 83~85 DEG C.
IR νmax(KBr)/cm-1: 3023.6,2998.7,1601.3,1541.2,1037.4,748.3,698.2.
1H-NMR(D6- DMSO, 400MHz) δ: 7.15-7.26 (m, 5H, ArH), 4.47 (q, 2H, J=7.0Hz), 3.36
(t, 2H, J=7.7Hz), 3.13 (t, 2H, J=7.7Hz), 1.46 (t, 6H, J=7.0Hz).
13C-NMR(D6- DMSO, 100MHz) δ: 159.1,151.5,147.7,140.5,128.9 (2C), 128.8 (2C),
126.6,66.2,31.6,25.4,14.2.
MS (EI): m/z (%): 271.5 [(M+H)+,100],293.3[(M+Na)+,83]。
Anal.calcd for C13H14N6O:C, 57.77；H,5.22；N,31.09；O,5.92；Found:C, 57.90；H,
5.20；N,31.15；O,5.93.
Embodiment 9
The present embodiment is specially 3- phenethyl -6- ethyoxyl-[1,2,4] triazole [4,3-b] heating balanced, and structural formula is as follows
Shown in Formulas I-i:
The specific preparation method of the 3- phenethyl -6- ethyoxyl of the present embodiment-[1,2,4] triazole [4,3-b] heating balanced is such as
Under:
In the reaction flask of 100mL cleaning, addition raw material 3- phenethyl -6- (3,5- dimethyl pyrazole -1- base)-[1,2,
Reaction mixture is heated to 70 DEG C of progress insulation reactions by 4] triazole [4,3-b] heating balanced 1g (3.1mmol) and methanol 30mL
7h is evaporated under reduced pressure after reaction, and extra methanol solvate is evaporated off, and a small amount of ice ethyl alcohol is added into residue and is stirred
Crystallization is mixed, makes that a large amount of yellow solid is precipitated, filtering, drying obtain target product 3- phenethyl -6- ethyoxyl-[1,2,4] three
Azoles [4,3-b] heating balanced, yield 0.55g, mass yield 69.6%.
Obtained product is subjected to corresponding structural analysis, concrete analysis structure is as follows:
Wherein fusing point mp are as follows: 98~100 DEG C.
IR νmax(KBr)/cm-1: 3097.9,2945.4,1579.6,1551.0,1040.9,744.8,707.4.
1H-NMR(D6- DMSO, 400MHz) δ: 7.15-7.26 (m, 5H), 4.47 (q, 2H, J=7.0Hz), 3.36 (t, 2H,
J=7.7Hz), 3.13 (t, 2H, J=7.7Hz), 1.46 (t, 6H, J=7.0Hz).
13C-NMR(D6- DMSO, 100MHz) δ: 159.8,151.5,147.8,140.5,128.9 (2C), 128.8 (2C),
126.8,57.0,31.6,25.4。
MS (EI): m/z (%): 257.3 [(M+H)+,100]。
Anal.calcd for C12H12N6O:C, 56.24；H,4.72；N,32.79；O,6.24；Found:C, 56.35；H,
4.71；N,32.85；O,6.22.
Embodiment 10
The present embodiment is specially 3- (4- aminomethyl phenyl) -6- methoxyl group-[1,2,4] triazole [4,3-b] heating balanced, structure
Formula is as shown in following formula I-j:
The preparation side of 3- (4- methoxyphenyl) -6- methoxyl group-[1,2,4] triazole [4,3-b] heating balanced of the present embodiment
Method is as follows:
In the reaction flask of 100mL cleaning, addition raw material 4- methylphenyl -6- (3,5- dimethyl pyrazole -1- base)-[1,
The temperature of reaction solution is warming up to reflux and carried out by 2,4] triazole [4,3-b] heating balanced 1g (3.3mmol) and ethyl alcohol 50mL, heating
Back flow reaction 7h carries out that extra alcohol solvent is evaporated off, then dehydrated alcohol is added into residue after reaction
10mL, then slow cooling makes that a large amount of yellow solids are precipitated, filters, drying obtains to 0 DEG C of -5 DEG C of stirring and crystallizing under stirring
To target product 3- (4- aminomethyl phenyl) -6- methoxyl group-[1,2,4] triazole [4,3-b] heating balanced, yield 0.45g, yield
52.9%.
Obtained product is subjected to corresponding structural analysis, concrete analysis structure is as follows:
Wherein fusing point mp are as follows: 143~145 DEG C.
IR νmax(KBr)/cm-1: 3085.9,2991.3,1528.6,1043.6,850.3.
1H-NMR(D6- DMSO, 400MHz) δ: 8.38 (d, 2H, J=8.6Hz), 7.19 (d, 2H, J=8.6Hz), 4.56
(q, 2H, J=7.0Hz), 3.83 (t, 3H, J=7.0Hz).
13C-NMR(D6- DMSO, 100MHz) δ: 159.2,152.2,144.3,136.2,129.5 (2C), 125.7 (2C),
123.6,66.4,21.3,14.2。
MS (EI): m/z (%): 257.2 [(M+H)+,100]。
Anal.calcd for C12H12N6O:C, 56.24；H,4.72；N,32.79；O,6.24；Found:C, 56.44；H,
4.71；N,32.65；O,6.26.
Embodiment 11
The present embodiment is specially 3- p-fluorophenyl -6- isobutoxy-[1,2,4] triazole [4,3-b] heating balanced compound,
Structural formula is as shown in following formula I-a:
The compound specific the preparation method is as follows:
In the clean reaction flask of 1000mL, addition raw material 3- p-fluorophenyl -6- (3,5- dimethyl pyrazole -1- base)-[1,
2,4] triazole [4,3-b] heating balanced 10g (34mmol) and isobutanol 300mL, then carries out heat temperature raising, and temperature is made to rise to 40 DEG C
Insulation reaction 6.0h is carried out under conditions of~45 DEG C；After reaction, it carries out removing extra iso-butanol solvent under reduced pressure, decompression is steamed
During evaporating control temperature 50 DEG C hereinafter, most solvent is evaporated off after, obtained residue, then, into residue
The ice ethyl alcohol of 100mL is added, then, being stirred keeps crystallization complete, and a large amount of yellow solid is precipitated, and filters, drying, drying temperature
Degree is 40 DEG C~45 DEG C, obtains target product 3- p-fluorophenyl -6- isobutoxy-[1,2,4] triazole [4,3-b] heating balanced, is produced
Amount is 7.1g, yield 72.4%.
Obtained product is subjected to corresponding structural analysis, concrete analysis result the same as analyzing result in embodiment 1 accordingly
Unanimously, which is not described herein again.
Embodiment 12
The present embodiment is specially 3- phenethyl -6- ethyoxyl-[1,2,4] triazole [4,3-b] heating balanced, and structural formula is as follows
Shown in Formulas I-i:
The specific preparation method of the 3- phenethyl -6- ethyoxyl of the present embodiment-[1,2,4] triazole [4,3-b] heating balanced is such as
Under:
In the reaction flask of 1000mL cleaning, addition raw material 3- phenethyl -6- (3,5- dimethyl pyrazole -1- base)-[1,2,
4] triazole [4,3-b] heating balanced 10g (31mmol) and methanol 300mL, reaction mixture is heated to flowing back, is maintained at reflux
Heat preservation back flow reaction 6h is carried out under state to be evaporated under reduced pressure after reaction, extra methanol solvate is evaporated off, toward residue
The middle a small amount of 150mL ice ethyl alcohol of addition is stirred crystallization, makes that a large amount of yellow solid is precipitated, filtering, drying obtain target product
3- phenethyl -6- ethyoxyl-[1,2,4] triazole [4,3-b] heating balanced, yield 6.5g, mass yield 82.2%.
Obtained product is subjected to corresponding structural analysis, concrete analysis result the same as analyzing result in embodiment 10 accordingly
Unanimously, which is not described herein again.
Application Example 1
Using respective compound obtained in above-described embodiment 1-12 as active constituent, medicine with anti-tumor activity is prepared
Object, specific drug agent system can be capsule, tablet or liquid preparation etc., can also be the form of dispersion.In the present embodiment
It is illustrated by specific implementation process of capsule.
This capsule is using the arbitrary compound that embodiment 1-12 is obtained as active constituent and pharmaceutically acceptable auxiliary
Material composition.The content of general active constituent is adjusted according to actual needs below 50%, preferably makes active constituent
Content controls below 10%.Here pharmaceutically acceptable auxiliary material can be plasticizer, adhesive, filler, lubricant,
Stabilizer, short taste agent etc..Filler therein is selected from lactose, sucrose, microcrystalline cellulose, starch, pre-paying starch, dextrin etc.
Deng；
Adhesive is selected from ethyl cellulose, polyvinylpyrrolidone (PVP) etc.；
Lubricant is selected from magnesium stearate, talcum powder, superfine silica gel powder etc.；Plasticizer is selected from glycerol, castor oil etc..
Short taste agent can be the pharmaceutically common short taste auxiliary material such as fructose, Abbas's sweet tea.
It chooses compound I-a to I-j obtained in above-described embodiment and shows that there is apparent antitumor work through vitro detection
Property.
Specific test method uses tetrazolium reduction method (mtt assay), selects human lung cancer A549, human placenia cancer thin
Born of the same parents strain Bewo and human breast carcinoma MCF-7, action time are 72 hours.
Specific test result is as shown in table 1, and the data in following table 1 are using I-a to I-h as drugs with function, to above-mentioned
Inhibiting effect (the IC of the corresponding tumor cell in vitro strain of the cell strain of selection50: μ g/mL) test result: with cis-platinum
It (Cisplatin) is check analysis to the inhibiting effect of corresponding tumor cell line.It is specific that test result is as follows shown in table 1:
Table 1:
| Samples | A549 | Bewo | MCF-7 |
| I-a | 14.27 | 25.00 | 4.15 |
| I-b | 27.51 | 28.28 | 7.31 |
| I-c | 14.92 | 23.42 | 2.24 |
| I-d | 1.99 | 26.32 | 3.05 |
| I-e | 12.00 | 23.00 | 2.70 |
| I-f | 18.58 | 23.48 | 7.96 |
| I-g | 20.75 | 28.88 | 6.46 |
| I-h | 5.86 | 5.60 | 0.76 |
| I-i | 20.37 | 22.49 | 2.48 |
| I-j | 16.4 | 14.6 | 1.21 |
| Cisplatin | 9.97 | 10.46 | 15.03 |
Data result in above-mentioned table 1 is the mean value for carrying out parallel laboratory test result three times.
Can be seen that cis-platinum from the data in above-mentioned table 1 has stronger resistance to make in the cell of A549, Bewo and MCF-7
With IC50Respectively 9.97 μ g/mL, 10.46 μ g/mL and 15.03 μ g/mL, with it is reported in the literature quite.And relative to cis-platinum
To the inhibiting effect of above-mentioned tumour cell, corresponding chemical combination of the invention equally there is preferable inhibition to make above-mentioned tumour cell
With, and some compound on tumor cell of the invention have stronger inhibiting effect, bioactivity is higher, and such as the present invention is implemented
Corresponding alkoxide compound obtained in example compares cis-platinum to the inhibiting effect (0.76-7.96 μ g/mL) of MCF-7 cancer cell
(15.03 μ g/mL) is eager to excel；And part of compounds such as I-d to the inhibiting effect (1.99 μ g/mL) of A549 and is better than cis-platinum (9.97 μ
g/mL).Thus, alkoxide triazol tetrazine compound of the invention has good anti-tumor activity, some even have
Good application prospect.As it can be seen that [1,2,4] triazole [4,3-b] heating balanced derivative compound of the invention is expected to apply and prevent
With treatment tumor disease.
Specific embodiment described in the present invention only illustrate the spirit of the present invention by way of example.The neck of technology belonging to the present invention
The technical staff in domain can make various modifications or additions to the described embodiments or replace by a similar method
In generation, however, it does not deviate from the spirit of the invention or beyond the scope of the appended claims.
It is skilled to this field although present invention has been described in detail and some specific embodiments have been cited
For technical staff, as long as it is obvious for can making various changes or correct without departing from the spirit and scope of the present invention.
Claims (10)
1. a kind of alkoxide triazol tetrazine kind compound, which is characterized in that the structural formula of the compound is as shown in following formula I:
In above-mentioned formula I, R1Selected from C1~C5Alkyl；R2Selected from phenyl, substituted-phenyl or substituted benzene alkyl；The substituted-phenyl choosing
From p-methoxyphenyl, halogenophenyl or C1~C3Alkyl-substituted phenyl；The substituted benzene alkyl is selected from benzyl or benzene second
Base.
2. alkoxide triazol tetrazine kind compound according to claim 1, which is characterized in that the R1Selected from methyl, second
Base, isobutyl group or isopropyl；R2It is selected from phenyl, p-methoxyphenyl, phenethyl, 2,4 dichloro benzene base, rubigan or right
Fluorophenyl.
3. a kind of preparation method of alkoxide triazol tetrazine kind compound, which is characterized in that this method includes by II chemical combination of formula
Object 6- (3,5- dimethyl pyrazole -1- base)-[1,2,4] triazole [4,3-b] heating balanced class compound and alkylol R1OH carries out anti-
It answers, obtains product type I compound；
R described above1Selected from C1~C5Alkyl；The R2Selected from phenyl, substituted-phenyl or substituted benzene alkyl；The substituted-phenyl
Selected from p-methoxyphenyl, halogenophenyl or C1~C3Alkyl-substituted phenyl；The substituted benzene alkyl is selected from benzyl or benzene second
Base.
4. the preparation method of alkoxide triazol tetrazine kind compound according to claim 3, which is characterized in that the alkyl
Alcohol R1OH is selected from ethyl alcohol, methanol, isopropanol or isobutanol.
5. the preparation method of alkoxide triazol tetrazine kind compound according to claim 3, which is characterized in that the reaction
Temperature be 40 DEG C~80 DEG C.
6. according to claim 3 or 4 or the preparation method of the 5 alkoxide triazol tetrazine kind compounds, which is characterized in that institute
State alkylol R1OH is used as reactant and solvent to use simultaneously, the alkylol R1OH is excessive.
7. the preparation method of alkoxide triazol tetrazine kind compound according to claim 6, which is characterized in that the formula II
Compound and alkylol R1The mass ratio of OH is 1:20~30.
8. according to claim 3 or 4 or the preparation method of the 5 alkoxide triazol tetrazine kind compounds, which is characterized in that anti-
It further include post-processing, the post-processing after answering specifically:
Reaction solution after reaction is carried out alkylol is distilled off, adding ice ethyl alcohol makes that solid is precipitated, and obtains product formula I
Compound.
9. a kind of application of alkoxide triazol tetrazine kind compound, which is characterized in that alkoxide as claimed in claim 1 or 2
Triazol tetrazine kind compound is used to prepare drug or functional food with anti-tumor activity.
10. the application of alkoxide triazol tetrazine kind compound according to claim 9, which is characterized in that described antitumor
Active drug includes the active constituent of alkoxide triazol tetrazine kind compound as claimed in claim 1 or 2 and pharmaceutically may be used
The auxiliary material of receiving.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810128673.3A CN108276415B (en) | 2018-02-08 | 2018-02-08 | A kind of alkoxide triazol tetrazine kind compound and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810128673.3A CN108276415B (en) | 2018-02-08 | 2018-02-08 | A kind of alkoxide triazol tetrazine kind compound and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108276415A CN108276415A (en) | 2018-07-13 |
| CN108276415B true CN108276415B (en) | 2019-07-05 |
Family
ID=62808063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810128673.3A Active CN108276415B (en) | 2018-02-08 | 2018-02-08 | A kind of alkoxide triazol tetrazine kind compound and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108276415B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113788835B (en) * | 2021-10-21 | 2022-08-26 | 台州职业技术学院 | Triazole tetrazine compound containing morpholine and quinoline ring and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101945874A (en) * | 2007-12-18 | 2011-01-12 | 法米诺克斯有限公司 | 3-substituted-4-0x0-3, 4-dihydro-imidazo- [5, 1-d] [1,2,3,5] -tetrazine-8-carboxylic acid amides as anticancer agents |
| CN102532141A (en) * | 2010-12-08 | 2012-07-04 | 中国科学院上海药物研究所 | (1,2,4)-triazolo-(4,3-b) (1,2,4)-triazine compounds, as well as preparation method and use thereof |
| CN103012410A (en) * | 2012-12-22 | 2013-04-03 | 台州职业技术学院 | [1,2,4] triazole [4,3-b] sym-tetrazine derivation compound and preparation method thereof |
| CN105968064A (en) * | 2016-05-06 | 2016-09-28 | 浙江工业大学 | Bis(m-methylphenyl) tetrazine dicarboxamide compound as well as preparation and application thereof |
-
2018
- 2018-02-08 CN CN201810128673.3A patent/CN108276415B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101945874A (en) * | 2007-12-18 | 2011-01-12 | 法米诺克斯有限公司 | 3-substituted-4-0x0-3, 4-dihydro-imidazo- [5, 1-d] [1,2,3,5] -tetrazine-8-carboxylic acid amides as anticancer agents |
| CN102532141A (en) * | 2010-12-08 | 2012-07-04 | 中国科学院上海药物研究所 | (1,2,4)-triazolo-(4,3-b) (1,2,4)-triazine compounds, as well as preparation method and use thereof |
| CN103012410A (en) * | 2012-12-22 | 2013-04-03 | 台州职业技术学院 | [1,2,4] triazole [4,3-b] sym-tetrazine derivation compound and preparation method thereof |
| CN105968064A (en) * | 2016-05-06 | 2016-09-28 | 浙江工业大学 | Bis(m-methylphenyl) tetrazine dicarboxamide compound as well as preparation and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| "Synthesis, antitumor evaluation and 3D-QSAR studies of [1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine derivatives";Xu, Feng 等;《Bioorganic & Medicinal Chemistry Letters》;20160724;第26卷(第19期);4580-4586 |
| "Synthesis, antitumor evaluation and molecular docking studies of [1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine derivatives";Xu, Feng 等;《Bioorganic & Medicinal Chemistry Letters》;20160504;第26卷(第13期);3042-3047 |
| "新型［1，2，4］三唑［4，3- b］均四嗪类化合物的合成及其抗癌活性";陈辉等;《合成化学》;20120831;第20卷(第4期);475-478 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108276415A (en) | 2018-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014244555B2 (en) | DNA-PK inhibitors | |
| WO2016127074A1 (en) | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors | |
| AU2017289317B2 (en) | Cyanoindoline derivatives as NIK inhibitors | |
| CN106661025B (en) | A kind of isethionate of cyclin dependent kinase inhibitor, its crystal form and preparation method | |
| CN110546145B (en) | Azaaryl derivative, preparation method and pharmaceutical application thereof | |
| CN111989329B (en) | Crystal form of mono-mesylate of deuterated 3- (4, 5-substituted aminopyrimidine) phenyl compound and preparation method thereof | |
| CN113061138A (en) | Triazole [5,4-d ] pyrimidone tricyclic compound and preparation method and application thereof | |
| CN112898314A (en) | Preparation and application of deubiquitinase inhibitor | |
| CN103097368B (en) | Be used for the treatment of the tricyctic lactone of cancer | |
| CN108276415B (en) | A kind of alkoxide triazol tetrazine kind compound and its preparation method and application | |
| CN112867717A (en) | Compounds useful as kinase inhibitors and uses thereof | |
| CN108864089B (en) | Indolopyridone drug molecule and preparation method and application thereof | |
| CN110655506B (en) | Preparation method of tegafur | |
| CN106632424A (en) | Copper chloride complex using 1-(2-pyridine)-9-hexyl-beta-carboline as ligand and synthesis method and application thereof | |
| CN106543208B (en) | Using 1 pyridine β carbolines as copper chloride (II) chelate of ligand and its synthetic method and application | |
| CN106632420B (en) | Using 1- (2- pyridines) -9- butyl-ss-carbolines as the chlorination copper complex and its synthetic method of ligand and application | |
| CN110655507B (en) | Preparation method of anti-tumor medicine tegafur | |
| CN106554362A (en) | A kind of copper chloride (II) chelate and its synthetic method and application with 1 pyridine β carbolines as part | |
| CN103254191A (en) | Substituted aryl tetracyclic antifungal compound as well as preparation method and application thereof | |
| CN103012410B (en) | [1,2,4] triazole [4,3-b] sym-tetrazine derivation compound and preparation method thereof | |
| Loksha et al. | A novel synthetic route for the anti-HIV drug MC-1220 and its analogues | |
| EP3697786A1 (en) | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase | |
| CN103044326A (en) | 5-bromo oxoisoaporphine, and synthesis method and application thereof | |
| CN107382941B (en) | Flavone derivative and preparation method and application thereof | |
| CN106632416B (en) | Using 1- (2- pyridines) -9- isopentyl-B-carboline as the chlorination copper complex and its synthetic method of ligand and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |